Management of Hepatic Encephalopathy in the Hospital Michael D. Leise, MD, John J. Poterucha, MD, Patrick S. Kamath, MD, W. Ray Kim, MD  Mayo Clinic Proceedings  Volume 89, Issue 2, Pages 241-253 (February 2014) DOI: 10.1016/j.mayocp.2013.11.009 Copyright © 2014 Mayo Foundation for Medical Education and Research Terms and Conditions

Figure 1 Management of a first episode of hepatic encephalopathy (HE), grade 1 or 2. aRifaximin is not Food and Drug Administration approved for overt HE. Mayo Clinic Proceedings 2014 89, 241-253DOI: (10.1016/j.mayocp.2013.11.009) Copyright © 2014 Mayo Foundation for Medical Education and Research Terms and Conditions

Figure 2 Management of recurrent episodes of hepatic encephalopathy (HE), grade 1 or 2. aRifaximin is not Food and Drug Administration approved for overt HE (OHE). abx = antibiotic; BCAA = branched-chain amino acid; LOLA = l-ornithine–l-aspartate; MELD = Model for End-Stage Liver Disease; PS = portosystemic. Mayo Clinic Proceedings 2014 89, 241-253DOI: (10.1016/j.mayocp.2013.11.009) Copyright © 2014 Mayo Foundation for Medical Education and Research Terms and Conditions

Figure 3 Management of a severe episode of hepatic encephalopathy (HE), grade 3 or 4.aRifaximin is not Food and Drug Administration approved for overt HE (OHE). BCAA = branched-chain amino acid; CT = computed tomography; dx = diagnostic; EEG = electroencephalogram; LOLA = l-ornithine–l-aspartate; MARS = Molecular Adsorbent Recirculating System; MELD = Model for End-Stage Liver Disease; NG = nasogastric tube. Mayo Clinic Proceedings 2014 89, 241-253DOI: (10.1016/j.mayocp.2013.11.009) Copyright © 2014 Mayo Foundation for Medical Education and Research Terms and Conditions